RPS6KB1 and familial pancreatic carcinoma: Therefore, the mechanism of metformin’s inhibition of P70S6K signaling activation that is mediated by inhibiting ERK phosphorylation in gemcitabine-resistant pancreatic cancer cells indicates the potential of metformin for clinical use.